Drug Trial Radar · NCT05058391
A Study of Elaprase in Children and Adults With Hunter Syndrome (Mucopolysaccharidosis II) in India
Last checked: Nov 20, 2026Latest source record: Jan 23, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
5
Actual
Start
Apr 21, 2022
Primary completion
Apr 6, 2024
Study completion Apr 18, 2024
Sponsor
- Lead sponsor
- TakedaTakeda (TAK)
- Sponsor type
- Industry
- First posted
- Sep 27, 2021
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main aim of this study is to learn more about the safety profile of Elaprase in Indian children and adults with hunter syndrome. Participants will receive Elaprase once per week over a 3-hour period which can be reduced to 1 hour as determined by the study doctor. Participants will need to visit the clinic weekly during the duration of the study.
Conditions
- Hunter Syndrome
Interventions
ElapraseBiological
Elaprase IV infusion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, Discontinuation Due to TEAEs and DeathTime frame: From start of the study drug administration up to Week 53
- Number of Participants With Adverse Drug Reactions (ADRs)Time frame: From start of the study drug administration up to Week 53
- Number of Participants With Infusion-related Reactions (IRRs)Time frame: From start of the study drug administration up to Week 53
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Institute of Child Health
Kolkata, India
All India Institute of Medical Sciences (AIIMS)
New Delhi, India
Sir Gangaram Hospital
New Delhi, India
SAT Hospital - Govt Medical College
Thiruvananthapuram, Kerala, India
JK Lone Hospital
Jaipur, Rajasthan, India
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.